Sysmex

Sysmex EBITDA Margin

The EBITDA Margin of Sysmex (6869.T) as of Oct 21, 2026 is 12.43 %. In the previous year, EBITDA Margin was 17.63 % — a change of -29.48% (lower).

EBITDA Margin

12.43 %

YoY

-29.48%

Last updated:

EBITDA Margin of Sysmex is 2026 12.43 % . EBITDA Margin of Sysmex was 2025 17.63 % . It decreases by -29.48% lower compared to the previous year.

The Sysmex EBITDA Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA Margin
Date
EBITDA Margin
Jan 1, 2019
20.71 JPY
Jan 1, 2020
18.05 JPY
Jan 1, 2021
16.12 JPY
Jan 1, 2022
19.12 JPY
Jan 1, 2023
17.70 JPY
Jan 1, 2024
16.75 JPY
Jan 1, 2025
17.63 JPY
Jan 1, 2026
12.43 JPY
The Sysmex EBITDA Margin history
YEAREBITDA MarginYoY
12.43 %-29.48%
17.63 %+5.26%
16.75 %-5.37%
17.70 %-7.45%
19.12 %+18.66%
16.12 %-10.71%
18.05 %-12.87%
20.71 %-2.58%
21.26 %+4.55%
20.34 %-15.38%
24.03 %+10.73%
21.70 %+11.67%
19.44 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Sysmex Stock analysis

What does Sysmex do? Sysmex Corp is a Japanese company that has been a leading provider of diagnostic and analytical laboratory systems and solutions for the healthcare industry since its founding in 1968. The company is headquartered in Kobe, Japan and employs over 9,000 people worldwide. History: Sysmex was founded by a group of young scientists in Japan who wanted to develop an automated blood cell analysis system to improve the high workload of manual blood analysis at the time. The company began developing this system and brought it to market in 1972. Business model: Sysmex focuses on the development, production, and sale of diagnostic systems and solutions for medical laboratories around the world. The company specializes in hematology, hemoglobinopathy, hemostasis, urinalysis, immunology, clinical chemistry, and molecular biology. Divisions: Sysmex Corp is divided into three main business divisions: 1. Diagnostic Systems: This division includes hematology, hemoglobinopathy, hemostasis, urinalysis, immunology, clinical chemistry, and molecular biology systems. Sysmex is one of the world's leading providers of hematology analysis devices and also offers molecular biology systems for the diagnosis and monitoring of infectious diseases and cancer. 2. Information Solutions: This division offers software and IT solutions that support laboratory management and the integration of laboratory data to optimize analysis processes. The company also offers solutions for automating laboratory processes and managing laboratory inventory. 3. Life Science: This division focuses on the development of products for the life sciences, particularly cell analysis and imaging, as well as production, processing, and storage of cell cultures. Sysmex is also involved in the production of devices for harvesting mesenchymal stem cells from adipose tissue. Products: Sysmex offers a variety of products, including: - Hematology analysis devices for determining blood cell parameters such as RBC, WBC, HGB, HCT, and platelets. - Hemostasis systems for analyzing blood coagulation. - Molecular biology systems for the diagnosis and monitoring of infectious diseases and cancer. - Urinalysis systems for analyzing urine samples for chemical and microscopic parameters. - Immunology analysis devices for determining specific proteins and antibodies in the blood. - Clinical chemistry analysis devices for analyzing chemical parameters in blood samples. - Software and IT solutions for optimizing laboratory processes and management. - Cell analysis and imaging systems for investigating cell morphology and functions. - Devices for harvesting mesenchymal stem cells from adipose tissue. In summary, Sysmex Corp is a global leader in diagnostic and analytical laboratory systems and solutions for the healthcare industry. In its nearly 50-year history, the company has developed and produced a wide range of products that enable laboratories to perform fast and accurate disease diagnosis. The company has also expanded its business into other areas such as information solutions and the life sciences. Sysmex is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Sysmex stock

EBITDA Margin of Sysmex is 12.43 % in 2026.

EBITDA Margin of Sysmex changed from 17.63 % to 12.43 %, representing a -29.48% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBITDA Margin Sysmex since 2006 – with annual values, charts, and detailed analysis.

EBITDA Margin shows what percentage of revenue converts to EBITDA. It normalizes for depreciation and capital structure differences.

A 'good' varies by industry and company stage. On Eulerpool, you can compare EBITDA Margin's Sysmex with sector peers and the industry average to assess whether it is attractive.

To evaluate EBITDA Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EBITDA Margin.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Margins — Sysmex

All Key Metrics — Sysmex